Myelodysplastic Syndromes (MDS)

Nursing Education Modules on MDS Disease Management and Patient Education

Innovations in the diagnosis, risk stratification, and treatment of myelodysplastic syndromes (MDS) provide hope for patients while creating challenges for their health care providers. Nurses play an integral role in providing patients with clear explanations, setting treatment expectations, and empowering them to be actively in their care decisions. 

Kirk R. Schultz, MD

Institution
British Columbia Children’s Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Pediatric
About
Dr. Kirk Schultz is a Professor at the University of British Columbia, BC Children’s Hospital, and the Child and Family research Institute (CFRI) who has published over 130 peer-reviewed articles in scientific journals. He is a Pediatric Hematologist/Oncologist focused on new therapies and rejection in Blood and Marrow Transplantation (BMT) and immune therapy of blood cancers.Dr. Schultz was the recipient of the CIHR/Wyeth Clinical Research Chair in Transplantation and is past chair of the Pediatric BMT Consortium the largest children’s BMT clinical trials group in the world. He was recently

Lukasz Gondek, M.D., Ph.D.

Institution
Johns Hopkins University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Dr. Gondek is a current Evans Fellow at Johns Hopkins University in the Department of Oncology, working with Dr. Amy Dezern on research related to signaling pathways in MDS stem cells. Dr. Gondek explained that the mechanism of progression in MDS is poorly understood, and he hopes through his work to clarify some of the factors that contribute to progression. He is the Principal Investigator on one pilot project currently underway within the MDS Clinical Research Consortium, working with a particular signaling pathway named the Hedgehog pathway. Dr. Gondek describes the Hedgehog (Hh) pathway

David Margolis, MD

Institution
Children’s Hospital of Wisconsin
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
David Margolis, MD, received his medical degree from the University of Wisconsin-Madison in 1989. He is currently a professor of pediatrics at the Medical College of Wisconsin, located in Milwaukee, and is program director of Children’s Hospital of Wisconsin’s Blood and Bone Marrow Transplant Program. His clinical and research interests include taking care of children and young adults with aplastic anemia as well as alternative donor blood and bone marrow transplants for children and young adults with aplastic anemia, sickle cell anemia and leukemia.

Blood Transfusion Safety and Risks

Negative side effects of blood transfusion therapy are uncommon. Blood banks, hospitals, and health-care providers take many precautions to minimize risks before each blood transfusion.

Blood banks test each unit of blood to find out its ABO type and Rh status. In the United States, after a hospital laboratory receives a blood unit from the blood bank, the laboratory tests the unit again.

 

Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.